Skip to content

Trial · Interventional

Not yet recruitingPhase 4Registry data

Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes

Short name MOTIVATE

Overview

Status
Not yet recruiting
Phase
Phase 4
Enrollment
164 participants (estimated)
Sponsor
Western University, Canada · Other
Design
Randomized · Single masking
Countries
1 country

Canada

Start
1 Sept 2026 (estimated)
Primary completion
1 May 2029 (estimated)
Completion
1 May 2029 (estimated)
First posted
20 Mar 2026
Last update posted
20 Aug 2026
Conditions
Type 2 Diabetes · Cognitive Decline in Older Adults

Timeline

1 trial · 1 not yet recruiting

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
20262027202820292030
  1. Ph 4

    MOTIVATE

    NCT07485062

    est. 1 Sept 2026 to est. 1 May 2029

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

Type 2 diabetes and low levels of physical activity are associated with an increased risk of cognitive decline in older adults. Improving blood sugar control and engaging in regular exercise may help support brain health and physical function in this population. The MOTIVATE study is a randomized clinical trial designed to examine the effects of supervised exercise and diabetes treatment with semaglutide, alone or in combination, on cognitive function, physical health, and brain-related outcomes in older adults with Type 2 diabetes. Participants will be assigned to one of four study groups involving exercise training, control exercise, semaglutide treatment, or standard diabetes care. Participants will complete supervised exercise sessions three times per week for 32 weeks, with some participants also receiving weekly semaglutide injections for 16 weeks. Assessments will include cognitive testing, physical and functional measures, blood-based metabolic markers, and brain imaging. This study aims to improve understanding of how exercise and diabetes treatments may support brain health in older adults with Type 2 diabetes.

Interventions

  • semaglutideDrug
  • Moderate-Intensity Resistance ExerciseBehavioral
  • Balance and Tone (BAT) ExerciseBehavioral

Arms4

  • Experimental

    Resistance Exercise + Semaglutide

    Participants assigned to this arm will receive injectable semaglutide once weekly for 16 weeks, in addition to participating in supervised moderate-intensity resistance exercise training three times per week for 32 weeks. Semaglutide will be administered during the first 16 weeks, followed by a 16-week exercise-only period.

  • Active comparator

    Standard of Care + Resistance Exercise

    Participants assigned to this arm will receive standard of care treatment for Type 2 diabetes for 16 weeks and participate in supervised moderate-intensity resistance exercise training three times per week for 32 weeks. No semaglutide will be administered during the study period.

  • Active comparator

    Semaglutide + Balance and Tone Exercise

    Participants assigned to this arm will receive injectable semaglutide once weekly for 16 weeks and participate in supervised balance-and-tone (BAT) exercise three times per week for 32 weeks. Semaglutide will be administered during the first 16 weeks, followed by a 16-week exercise-only period.

  • Active comparator

    Standard of Care + Balance and Tone Exercise

    Participants assigned to this arm will receive standard of care treatment for Type 2 diabetes for 16 weeks and participate in supervised balance-and-tone (BAT) exercise three times per week for 32 weeks. No semaglutide will be administered during the study period.

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Trail Making Test (TMT) Part A and B

    Time frame · Baseline (Week 0), Midpoint (Week 16), Endpoint (Week 32)

    Registry description

    Executive function will be assessed using the Trail Making Test (TMT), Parts A and B. The TMT measures visual attention, processing speed (Part A), and executive function/set-shifting ability (Part B). Time to completion (seconds) will be recorded, with faster completion times indicating better performance.

Secondary outcomes(20)
  1. Montreal Cognitive Assessment (MoCA)

    Time frame · Baseline (Week 0), Midpoint (Week 16), and Endpoint (Week 32)

    Registry description

    A 30-point cognitive screening tool designed to detect mild cognitive impairment. Domains assessed include attention, executive function, memory, language, visuoconstructional skills, abstraction, calculation, and orientation. Measurement Scale: Total scores range from 0 to 30. Higher scores indicate better cognitive performance. For this study, a score of ≥26 is considered "normal" cognitive function, while scores below this threshold (typically 18-25) may suggest mild cognitive impairment (MCI).

  2. Mini-Mental State Examination (MMSE)

    Time frame · Baseline (Week 0), Midpoint (Week 16), and Endpoint (Week 32)

    Registry description

    An 11-item screening tool assessing global cognitive function across orientation, registration, attention and calculation, recall, and language. Scores range from 0-30, with higher scores indicating better cognitive function.

  3. Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog-11)

    Time frame · Baseline (Week 0), Midpoint (Week 16), and Endpoint (Week 32)

    Registry description

    A cognitive test with an 11-task battery assessing memory, language, praxis, attention, and orientation. Widely used in clinical trials to evaluate cognitive dysfunction and disease progression in Alzheimer's disease and related conditions. A score ranges from 0 to 70. Higher scores represent greater cognitive deficit (impairment), with scores of 18 or higher typically indicating cognitive impairment.

  4. Digit Span (Forward and Backward)

    Time frame · Baseline (Week 0), Midpoint (Week 16), and Endpoint (Week 32)

    Registry description

    A measure of working memory requiring participants to recall increasingly long sequences of numbers in both forward and reverse order. The final score is usually the total correct sequences (0-14 correct) and the longest sequence length achieved (e.g., if a user correctly repeats a 7-digit string, their span is 7). A minimum sequence length of 3 (forward) or 2 (backward) and a maximum sequence of 9 (forward) or 8 (backward) can be achieved. High scores indicate better performance.

  5. Stroop Color-Word Test

    Time frame · (Week 0), Midpoint (Week 16), and Endpoint (Week 32)

    Registry description

    Assesses selective attention, processing speed, and cognitive inhibition. Participants are required to identify ink colors while inhibiting automatic word reading. Completion time and/or errors are recorded. Faster completion times and fewer errors indicate better performance.

  6. Rey Auditory Verbal Learning Test (RAVLT)

    Time frame · Baseline (Week 0), Midpoint (Week 16), and Endpoint (Week 32)

    Registry description

    A measure of episodic verbal learning and memory. Participants are read a list of words across multiple trials and asked to recall as many words as possible immediately and after a delay. The total number of words recalled immediately and after a delay is recorded. Additionally, a learning rate is calculated across the number of trials. More words recalled and faster learning rates indicate better performance.

  7. Digit Symbol Substitution Test (DSST)

    Time frame · Baseline (Week 0), Midpoint (Week 16), and Endpoint (Week 32)

    Registry description

    Administered using Inquisit software (Millisecond Software) using a computer, this is a timed task assessing processing speed, attention, and visuomotor coordination. Participants use a reference key to match symbols with corresponding numbers within a fixed time period. Total correct responses are recorded. Greater correct responses correspond with better performance.

  8. NIH Toolbox Flanker Task

    Time frame · Baseline (Week 0), Midpoint (Week 16), and Endpoint (Week 32)

    Registry description

    A computerized task assessing attention and inhibitory control. Participants respond to the direction of a central target stimulus while ignoring flanking distractors. The task is administered via the NIH Toolbox platform using a touchscreen or keyboard response on a tablet or computer device. Reaction time and accuracy are automatically recorded. Faster reaction times and greater accuracy correspond with better performance.

  9. Timed Up and Go (TUG) Test

    Time frame · Baseline (Week 0), Midpoint (Week 16), and Endpoint (Week 32)

    Registry description

    Used to assess mobility. Participants are seated in a chair and must stand up, walk a distance of 3 meters at their usual pace, turn around, return to their chair, and sit back down. The time to complete each of two separate trials is recorded in seconds.

  10. Short Physical Performance Battery (SPPB)

    Time frame · Baseline (Week 0), Midpoint (Week 16), and Endpoint (Week 32)

    Registry description

    Used to assess gait speed, balance, and lower extremity physical function using tasks that mimic daily activities; includes three tasks: (1) Standing Balance Task: participants stand unassisted (side-by-side standing, semi-tandem standing, and tandem standing) for a period of 10 seconds each; (2) Walking Speed Task: participants walk 4 meters at their usual pace; and (3)Chair Stand Test: participants stand up from a chair 5 times consecutively (without the use of their arms if possible). Time to complete tasks 2 and 3 is recorded in seconds. A score between 0 and 12 is assigned based on the above measures. A higher score indicates better daily physical function.

  11. Six-Minute Walk Test

    Time frame · Baseline (Week 0), Midpoint (Week 16), and Endpoint (Week 32)

    Registry description

    Used to assess aerobic fitness. Participants walk the furthest distance they can achieve in a total of 6 minutes. The total distance walked in meters is recorded. The greater the distance, the better aerobic fitness.

  12. Grip Strength Dynamometry

    Time frame · Baseline (Week 0), Midpoint (Week 16), and Endpoint (Week 32)

    Registry description

    Grip strength will be assessed using a calibrated handheld dynamometer to measure maximal voluntary isometric force of the dominant hand, providing an index of overall muscular strength. Measured in kgs.

  13. One-repetition maximum (1RM) strength testing

    Time frame · Third Exercise Class, Midpoint (Week 16), and Endpoint (Week 32)

    Registry description

    One-repetition maximum is a physical measure of an individual's maximum muscle strength during a single repetition and is used to determine the desired load for resistance training. Exercise includes leg press, latissimus pulldown, leg curl, chest press, bicep curls, tricep extensions, and pulley rows. Measured in kgs.

  14. Mean Cortical Thickness

    Time frame · Baseline (Week 0) and Endpoint (Week 32)

    Registry description

    The average distance between the white matter surface and the pial (outer) surface across the entire cerebral cortex and by region. Automated vertex-wise calculation of the distance between the gray/white matter boundary and the gray matter/CSF boundary. Millimeters (mm). Greater thickness is typically better.

  15. Resting-state functional connectivity

    Time frame · Baseline (Week 0) and Endpoint (Week 32)

    Registry description

    Participants will be asked to remain as still as possible with eyes open while a functional scan is acquired to assess intrinsic resting-state brain networks. Measured as Fisher-z transformed correlation coefficients (z). Higher values represent stronger functional synchronization.

  16. White Matter Fractional Anisotropy (FA)

    Time frame · Baseline (Week 0) and Endpoint (Week 32)

    Registry description

    A diffusion tensor imaging metric that measures the "directionality" of water diffusion within white matter tracts. It reflects the organization and integrity of the myelin and axonal membranes. Calculated from the diffusion tensor at each voxel; typically averaged across major tracts (e.g., Corpus Callosum, Cingulum). Values: Scale from 0 to 1 (unitless). A value of 1 indicates perfectly directional diffusion (healthy, organized white matter), while a decrease in FA indicates axonal degradation, demyelination, or "leaky" white matter.

  17. Total Gray Matter & White Matter Volumes

    Time frame · Baseline (Week 0) and Endpoint (Week 32)

    Registry description

    The global volume of the brain's neuronal cell bodies (gray matter) and myelinated axons (white matter) using automated whole-brain segmentation. Measured in cubic millimeters (mm\^3). Reduced total gray matter volume indicates global atrophy. White matter volume changes can indicate loss of structural connectivity.

  18. Subcortical Gray Matter Volume

    Time frame · Baseline (Week 0) and Endpoint (Week 32)

    Registry description

    The total volume of deep brain structures, most notably the hippocampus, thalamus, and amygdala using automated whole-brain segmentation. Measured in cubic millimeters (mm\^3). Reduced volume typically indicates brain atrophy.

  19. White Matter Hyperintensity (WMH) Volume

    Time frame · Baseline (Week 0) and Endpoint (Week 32)

    Registry description

    A measure of "leukoaraiosis" or white matter lesions, which appear as bright spots on T2-weighted magnetic resonance imaging (MRI) scans. These are primary markers of small vessel disease and vascular brain aging. Automated or semi-automated segmentation (e.g., via FreeSurfer's aseg or specialized toolboxes like BIANCA/LST) on T2- images. Measured as total volume in cubic millimeters (mm\^3) or as a percentage of Total Intracranial Volume (%ICV). Lower is better. Higher WMH volumes are strongly associated with hypertension, diabetes, and increased risk for stroke and vascular dementia.

  20. Fasting Blood Glucose (FBG) Measurement

    Time frame · Baseline (Week 0), Midpoint (Week 16), Endpoint (Week 32)

    Registry description

    Capillary blood samples will be obtained via finger prick and analyzed using a calibrated glucometer to determine fasting blood glucose (FBG) levels (expressed in mmol/L). Fasting is defined as the absence of caloric intake for a minimum of 8 hours. Glycemic status is categorized according to the following thresholds: Prediabetes Risk: 6.0-6.9 (mmol/L), Diabetes: ≥7.0 (mmol/L)

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 65 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: 1. Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial. 2. Community-dwelling 3. Male or female 4. Age ≥ 65 at the time of signing informed consent 5. Glycated hemoglobin levels of ≥7% (i.e., A1c levels high enough to see intervention-related changes and increase eligibility for recruitment, but can exercise safely) 6. Eligible for the Ontario Drug Benefit (inadequate glycemic control and on max tolerated dose of metformin or metformin contraindicated or inappropriate) 7. Score \>24/30 on the Mini-Mental State Exam (MMSE) 8. Score \>6/8 on the Lawton Instrumental Activities of Daily Living Scale (IADL) 9. Have visual acuity of \>20/40 with or without corrective lenses 10. Speak and understand English fluently 11. Complete the Physical Activity Readiness Questionnaire (PAR-Q+) and obtain physician clearance to start a supervised exercise program 12. Comfortable with a blood draw 13. Not currently engaging in structured resistance exercise more than once per week Exclusion Criteria: 1. Have a medical condition for which semaglutide or exercise is contraindicated 2. Use of a GLP-1 receptor agonist in the past 6 months (i.e., offers removal of Semaglutide from the system as it has a half-life of around 1 week; thus, 8-10 weeks are required for a washout. 3\) Have engaged regularly (\>1/week) in aerobic or RE within the past 6 months 4) Have a neurodegenerative disease (i.e., dementia) or psychiatric condition 5) Have had untreated depression in the past 6 months (6) Have experienced a recent vascular incident (i.e., stroke, myocardial infarction in the last 6 months.) (7) Have severe peripheral neuropathy, an active foot wound, or severe musculoskeletal/joint disease (8) Active or untreated retinopathy (9) Taking psychotropic medications (excluding those for the treatment of depression)

PepBank is a research reference. Talk to a doctor before you use any peptide.